BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Bicara Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$17.47+0.69 (+4.11%)
Close on Oct 19, 2026
- Market cap
- $1.19B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.78 (−4.27%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.19B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.53
- Dividend yield
- –
- Free cash flow yield
- -11.40%
Fundamentals
- Net income
- -$185.36M
- EPS, diluted
- -$2.52
- Free cash flow
- -$135.25M
- Book value per share
- $6.90
- Diluted shares
- 68M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$201.99M
Net income
-$185.36M
EPS, diluted
–
Free cash flow
-$135.25M
Reported periodTrailing twelve months